Shanghai Xinxing Pharmaceutical Co., Ltd.
Shanghai Xinxing Pharmaceutical Co., Ltd. was established in August 2000. It was co-sponsored by China Xinxing (Group) Corporation and other units. It was restructured on the basis of the Shanghai Xinxing Blood Products Research Institute of the Ministry of Health of the General Logistics Department of the People’s Liberation Army, with a registered capital of 164 million yuan. It is now controlled by China National Pharmaceutical and Health Industry Co., Ltd. (China National Pharmaceutical 600056). It is a national designated manufacturer of blood products. It is mainly engaged in the production and sales of blood products. It is a high-tech export-oriented biology integrating scientific research, production and sales Pharmaceutical companies.
The type and quantity of blood products are among the best in the industry. The main products include: human albumin, human prothrombin complex, human fibrinogen, etc. The company has been recognized as a national key high-tech enterprise by the Ministry of Science and Technology, Shanghai City high-tech enterprises, Shanghai-level enterprise technology centers, Pudong New Area enterprise R&D institutions, etc.
Xinxing Pharmaceutical commissioned Gabriton Technology to carry out intelligent access control transformation for the workshop protein separation area, logistics channel, protein refinement area, factor refinement area, and bottle washing area. The number of personnel is monitored dynamically in real time. The system assigns corresponding access rights for all types of personnel, monitors and controls the number of people entering the clean area in real time, regulates the behavior of employees entering and exiting the production area, and realizes intelligent and accurate management of personnel entering and exiting the clean area.